Clinical Trials Logo

Nasopharyngeal Carcinoma clinical trials

View clinical trials related to Nasopharyngeal Carcinoma.

Filter by:

NCT ID: NCT03908372 Recruiting - Clinical trials for Concurrent Chemoradiotherapy

Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma

Start date: June 15, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to optimize treatment strategies for patients with stage II and III nasopharyngeal carcinoma, reduce the side effects related to treatment and improve the quality of life.

NCT ID: NCT03907826 Recruiting - Clinical trials for Recurrent Nasopharyngeal Carcinoma

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

Start date: March 1, 2020
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized controlled, phase III clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of PD-1 antibody with chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma patients.

NCT ID: NCT03906058 Completed - Clinical trials for Nasopharyngeal Carcinoma

Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy

Start date: April 29, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this single arm, phase Ⅱ clinical trial is to evaluate the efficacy and safety of Anlotinib Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma after failure of no less than second-line chemotherapy or targeted therapy

NCT ID: NCT03904225 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis

Start date: December 14, 2018
Phase: Phase 2
Study type: Interventional

oral administration of Tegio capsules for 12 months for NPC patients with high risk of metastasis (AJCC stage T3-4N2M0 or T1-4N3M0) was tested trying to reduce distant metastasis,safety was also evaluated.

NCT ID: NCT03891953 Active, not recruiting - Melanoma Clinical Trials

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

Start date: May 7, 2019
Phase: Phase 1
Study type: Interventional

This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior anti-PD-1/PD-L1 therapy, or subjects with NPC. After the determination of the MTD/RD for a particular treatment arm, dose expansion will further assess safety, tolerability, PK/PD, and anti-tumor activity of each regimen at the MTD/RD.

NCT ID: NCT03890185 Active, not recruiting - Clinical trials for Nasopharyngeal Cancer

Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC

Start date: October 1, 2012
Phase: Phase 2
Study type: Interventional

The central hypothesis is to test Low Dose Fraction Radiotherapy (LDFRT), as a potentiator of Docetaxel and Cisplatin efficacy in locally advanced nasopharyngeal cancer.

NCT ID: NCT03876574 Completed - Clinical trials for Nasopharyngeal Carcinoma

Hepatic Artery Infusion Pump for NPC Liver Metastases

Start date: January 1, 2011
Phase: Phase 1
Study type: Interventional

A retrospective clinical trial to study the safety and effectiveness of hepatic arterial infusion (HAI) in treating patients who have nasopharyngeal carcinoma metastatic to the liver. Hepatic-direction drug administration improves the control power for intra-hapatic lesions.

NCT ID: NCT03866967 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma

Start date: March 27, 2019
Phase: Phase 2
Study type: Interventional

This is a multicenter, single-arm open-label, phase II study to evaluate the anti-tumor activity, safety, PK and immunogenicity of AK105 (Anti-PD1 antibody) in patients with metastatic nasopharyngeal carcinoma who have progressed after at least 2 prior lines of systemic chemotherapy (of which one of them must be platinum-based chemotherapy).

NCT ID: NCT03855020 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

Serial Epstein-Barr Virus DNA Surveillance in Nasopharyngeal Carcinoma Patients

Start date: May 9, 2019
Phase:
Study type: Observational

Endemic nasopharyngeal carcinoma (NPC) is invariably associated with Epstein-barr virus (EBV) infection. Plasma EBV DAN detected by polymerase chain reaction (PCR)-based assays can provide important informations of disease screening, disease relapse, and risks classification. In this study, the investigators will explore the impact of serial plasma EBV DNA during chemotherapy and radiotherapy on initial tumor response and long-term survival in patients with non-metastatic nasopharyngeal carcinoma

NCT ID: NCT03854838 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.

Start date: May 1, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of intensity-modulated radiation therapy combined with toripalimab in patients with the unresectable locally recurrent nasopharyngeal carcinoma.